KRAS mutation status in the prediction of pancreatic tumor response after neoadjuvant systemic therapy and magnetic resonance-guided SBRT.
709 Background: Stereotactic body radiotherapy (SBRT) has been incorporated into multi-
modality treatment of locally advanced and borderline resectable pancreatic ductal …
modality treatment of locally advanced and borderline resectable pancreatic ductal …
[HTML][HTML] Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant …
Purpose The purpose of this study was to determine if somatic mutations are associated with
clinical and pathologic outcomes in patients with borderline resectable pancreatic cancer …
clinical and pathologic outcomes in patients with borderline resectable pancreatic cancer …
KRAS and NOTCH1/2 Mutations are Associated With Pathologic and Clinical Outcomes in Localized Pancreatic Cancer Treated With Neoadjuvant Chemotherapy and …
AV Reddy, C Hill, S Sehgal, D Ding… - International Journal of …, 2021 - redjournal.org
Purpose/Objective (s) The role of radiation for pancreatic cancer remains controversial with
heterogeneous clinical response. Characterization of molecular biomarkers that predict …
heterogeneous clinical response. Characterization of molecular biomarkers that predict …
Impact of KRAS mutational status on outcomes in patients with pancreatic cancer (PDAC).
LX Ma, GH Jang, A Zhang, RE Denroche, A Dodd… - 2021 - ascopubs.org
4142 Background: KRAS mutations (m)(KRASm) are present in over 90% of pancreatic
adenocarcinomas (PDAC) with a predominance of G12 substitutions. KRAS wildtype (WT) …
adenocarcinomas (PDAC) with a predominance of G12 substitutions. KRAS wildtype (WT) …
Outcomes of pancreatic ductal adenocarcinoma (PDAC) patients treated with neoadjuvant stereotactic body radiation therapy (SBRT) or conventionally fractionated …
F Zhu, H Wang, H Ashamalla - 2021 - ascopubs.org
e16209 Background: Hypothesis: Neoadjuvant SBRT can improve survival when compared
to CFRT in PDAC patients who received chemotherapy. Past retrospective studies have …
to CFRT in PDAC patients who received chemotherapy. Past retrospective studies have …
Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and …
Background: Neoadjuvant therapy response correlates with survival in multiple
gastrointestinal malignancies. To potentially augment neoadjuvant response for pancreas …
gastrointestinal malignancies. To potentially augment neoadjuvant response for pancreas …
Survival outcomes in the modern era for localized pancreatic cancer with multi-agent chemotherapy and stereotactic body radiation therapy.
444 Background: The benefit of stereotactic body radiation therapy (SBRT) in the
neoadjuvant setting for patients with localized pancreatic adenocarcinoma (PDAC) remains …
neoadjuvant setting for patients with localized pancreatic adenocarcinoma (PDAC) remains …
Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity‐modulated radiation therapy (IMRT) in …
BC Chapman, A Gleisner, D Rigg… - Journal of Surgical …, 2018 - Wiley Online Library
Background and Objectives To compare outcomes in patients receiving neoadjuvant
stereotactic body radiation therapy (SBRT) with those receiving intensity‐modulated …
stereotactic body radiation therapy (SBRT) with those receiving intensity‐modulated …
A single-center analysis of 30-and 90-day post-pancreatectomy complications in patients undergoing neoadjuvant radiation with EBRT versus MRI-guided SBRT.
572 Background: Stereotactic MRI-guided adaptive radiation therapy (SMART) is being
investigated for enhanced efficacy in locally advanced, borderline resectable and medically …
investigated for enhanced efficacy in locally advanced, borderline resectable and medically …
Borderline Resectable Pancreatic Cancer: Impact on Neoadjuvant Response Post Integration of MRI Guided Adaptive Radiation Therapy
M Adams, N Nardella, JMM Bryant, RF Palm… - International Journal of …, 2023 - redjournal.org
Purpose/Objective (s) The optimal neoadjuvant therapy regimen for patients with borderline
resectable pancreas cancer (BRPC) remains to be defined, with a recent ALLIANCE study …
resectable pancreas cancer (BRPC) remains to be defined, with a recent ALLIANCE study …